摘要
宫颈癌在全球女性恶性肿瘤中的发病率排名第四,是女性癌症相关死亡的第二大主要原因。尽管近年来,各国逐渐完善了宫颈癌癌前病变系统性的筛查以及人们进行HPV疫苗的接种,但往往诊断时大多数已是中晚期。同步放化疗是局部晚期宫颈癌的标准治疗方案,部分宫颈癌患者表现出对辐射的抵抗,从而导致不良的预后,因此,如何提高宫颈癌放疗疗效,降低宫颈癌细胞放射抵抗性成为了如今研究的关键切入点。宫颈癌的放疗敏感性通常与基因表达、RNA调控、肿瘤微环境及免疫疗法等多种因素有关。虽然其中有些机制尚未完全明确,但其对宫颈癌治疗及预后上有很大的应用前景。
Cervical cancer is the fourth most common malignancy in women worldwide and the second leading cause of cancer-related death in women. Although in recent years, countries have gradually im-proved the systematic screening of cervical cancer precancerous lesions and people to carry out HPV vaccination, but often the diagnosis is already in the middle and advanced stage. Synchronized chemoradiotherapy is the standard treatment for locally advanced cervical cancer, and some cervi-cal cancer patients show resistance to radiation, leading to poor prognosis. Therefore, how to im-prove the curative effect of cervical cancer radiotherapy and reduce the radiation resistance of cer-vical cancer cells has become a key entry point for current research. The radiotherapy sensitivity of cervical cancer is usually related to gene expression, RNA regulation, tumor microenvironment and immunotherapy. Although some of these mechanisms are not fully understood, they have great ap-plication prospects in the treatment and prognosis of cervical cancer.
出处
《临床医学进展》
2023年第2期1933-1939,共7页
Advances in Clinical Medicine
